[Sporobakterin impact on atherogenic dyslipidemia at patients with intestinal dysbacteriosis].
The aim was to evaluate the correlation of intestinal microflora with indicators of lipid metabolism and the possibility of its correcting with sporobakterin. 38 patients from gastroenterological department (men - 18 women - 20, average age - 54,00 +/- 13,59 years), trapped in a random 5% sample. Were assessed the state of the luminal microflora in the large intestine and total cholesterol, b-lipoprotein (b-PL) and HDL in serum levels. Fence, preparation and sowing of faeces were carried out according to the methodical recommendations of N. M. Gracheva et al. (1986). Counting and smear from the colonies of one species were made after a day of incubation. Lipid fraction of serum was evaluated on biochemical analyzer Cobas Integra 400 (Roche, Switzerland). 15 patients with intestinal disorders of microbiocenosis and hypercholesterolemia, was conducted drug treatment with "Sporobakterin liquid, a suspension for oral use" (OOO "Bacor", Russia) for a recommended scheme. Were assessed serum levels of total cholesterol, HDL, and beta-LP, composition of intestinal microflora, the body mass before and after treatment. Statistical analysis was conducted using methods of variation statistics. it was revealed a positive effect of the sporobakterin on intestinal microflora and statistically significant reduction in total cholesterol and b-LP, a tendency to body weight reduce. The results indicated the influence of intestinal microflora on the atherogenic fractions of serum and the possibility of their correction with a sporobakterin.